The MELD score helps to estimate prognosis for pediatric patients with end-stage liver disease, and is used to prioritize transplant recipients.
PELD Score = 10* (0.480 * ln(bilirubin) + 1.857 * ln(INR) - 0.687 * ln(albumin) + 0.436 (if patient < 1 year: scores for patients listed for liver transplantation before the patient's first birthday continue to include the value assigned for age (< 1 Year) until the patient reaches the age of 24 months) + 0.667 (if patient has growth failure (<-2 Standard deviation))
Original/Primary ReferenceMcDiarmid SV, Anand R, Lindblad AS; Principal Investigators and Institutions of the Studies of Pediatric Liver Transplantation (SPLIT) Research Group. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation.Transplantation. 2002 Jul 27;74(2):173-81.
ValidationShinkai M, Ohhama Y, Take H, Fukuzato Y, Fujita S, Nishi T. Evaluation of the PELD risk score as a severity index of biliary atresia. J Pediatr Surg. 2003 Jul;38(7):1001-4.
Other ReferencesShneider BL, Neimark E, Frankenberg T, Arnott L, Suchy FJ, Emre S. Critical analysis of the pediatric end-stage liver disease scoring system: a single center experience.Liver Transpl. 2005 Jul;11(7):788-95.Bourdeaux C, et al. PELD score and posttransplant outcome in pediatric liver transplantation: a retrospective study of 100 recipients. Transplantation. 2005 May 15;79(9):1273-6.Barshes NR, et. al.The pediatric end-stage liver disease (PELD) model as a predictor of survival benefit and posttransplant survival in pediatric liver transplant recipients.Liver Transpl. 2006 Mar;12(3):475-80.
About the Creator
Suzanne McDiarmid, MD, is the chief of pediatric gastroenterology and the director of the UCLA Intestinal Transplant Program and Intestinal Failure Center at UCLA Medical Center. She is also a professor of pediatrics at the UCLA School of Medicine. Dr. McDiarmid researches liver and pancreatic transplantation.
To view Dr. Suzanne McDiarmid's publications, visit PubMed